Development of Treatment Algorithm for Eradication of Helicobacter Pylori Based on Antibiotic Susceptibility Test
试验速览
- 阶段
- 不适用
- 入组人数
- 123
- 试验地点
- 1
- 主要终点
- eradication rate of Helicobacter pylori
研究概览
简要总结
Helicobacter pylori eradication (H. pylori) rates with clarithromycin-based triple therapy are declining, and an alternative strategy is needed urgently. The investigators sought to compare the efficacy of pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy vs. concomitant therapy for H. pylori eradication in a region with high rates of multiple drug resistance.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •positive results of rapid urease test
排除标准
- •liver cirrhosis,
- •chronic kidney disease,
- •bleeding tendency,
- •allergy to antibiotics
研究组 & 干预措施
Susceptibility-guided group
Drugs according to antimicrobial susceptibility-guided treatment
干预措施: eradication of Helicobacter pylori (Drug)
triple therapy group
Drugs - Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk
干预措施: eradication of Helicobacter pylori (Drug)
concomitant therapy group
Drugs - Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk
干预措施: eradication of Helicobacter pylori (Drug)
结局指标
主要结局
eradication rate of Helicobacter pylori
时间窗: the H. pylori status was checked 4 weeks aft er the end of treatment using the 13 C-urea breath test.
次要结局
未报告次要终点
研究者
Jie hyun Kim
Associate Professor
Gangnam Severance Hospital